Peyronie’s disease – intralesional pharmacotherapy opportunities

Kliknij autora aby wyszukać wszystkie publikowane przez niego artykuły:
Jacek Karaszewski, Barbara Darewicz

1 (46) 2016 s. 97–100
Click to return to issue contents
97_1_46_2016.pdf
Digital version of article (in PDF file)

Fraza do cytowania: Karaszewski J., Darewicz B. Peyronie’s disease – intralesional pharmacotherapy opportunities. Polski Przegląd Nauk o Zdrowiu. 2016;1(46):97–100.

Peyronie’s disease is a rare urological illness, which leads to penile curvature, as a result of the fibrotic plaque formation in the tunica albuginea of corpus cavernosum of the penis. In extreme cases, it can prevent sexual intercourse. The etiology of the disease has not been explained so far. One of the possibilities of the treatment, mainly in the early phase of the disease is local pharmacotherapy by injection. The only drug approved by the US Food and Drug Administration (FDA) for the treatment of Peyronie’s disease is a collagenase clostridium histolyticum. This is due to insufficient knowledge of the pathophysiology of the disease and the lack of accurate, placebo controlled studies conducted on a statistically significant group of patients. The paper presents the most important active substances, which can contribute to treatment of the effects of Peyronie’s disease.

Key words: urology, Peyronie’s disease, penile curvature, intralesional treatment.



Copyright © 1989–2019 Polish Review of Health Sciences. All rights reserved.